Hinge Health
Valuation each multiple against its own 5-year range
Vs. peers Health Information Services
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Hinge Health (HNGE) | 8.60B | 51.68 | 28.71 | 0.00% |
| Veeva Systems (VEEV) | 43.10B | 43.64 | 5.80 | 0.00% |
| BrightSpring Health Services (BTSG) | 12.50B | 33.78 | 5.75 | 0.00% |
| Tempus AI (TEM) | 9.86B | -50.98 | 19.70 | 0.00% |
| HealthEquity (HQY) | 7.84B | 34.21 | 3.94 | 0.00% |
| Doximity (DOCS) | 5.13B | 39.90 | 5.52 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 3.4% below Morningstar's fair value estimate.
Fair value
Hinge Health Inc earns a 2-star quantitative star rating, illustrating our stance that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 6% premium over our quantitative fair value estimate of $109.33 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.
The firm's valuation metrics weaken our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its book value yield of 3.2%, which sits in the bottom 10% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are overvalued.
The firm's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 8.3%, for example, falls in the bottom 10% compared with peers globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which further promotes our unfavorable price/fair value ratio.
Economic moat
The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.
By Quantitative Equity Report
Quote time 2026-11-20 20:02:33 · For reference only, not investment advice and not tailored to your situation.
Hinge Health discussion 0 comments